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The role of sleep and sleep disorders 
in the development, diagnosis, and 
management of neurocognitive 
disorders
Michelle A. Miller*
Warwick Medical School, University of Warwick, Coventry, UK
It is becoming increasingly apparent that sleep plays an important role in the mainte-
nance, disease prevention, repair, and restoration of both mind and body. The sleep and 
wake cycles are controlled by the pacemaker activity of the superchiasmic nucleus in the 
hypothalamus but can be disrupted by diseases of the nervous system causing disor-
dered sleep. A lack of sleep has been associated with an increase in all-cause mortality. 
Likewise, sleep disturbances and sleep disorders may disrupt neuronal pathways and 
have an impact on neurological diseases. Sleep deprivation studies in normal subjects 
demonstrate that a lack of sleep can cause attention and working memory impairment. 
Moreover, untreated sleep disturbances and sleep disorders such as obstructive sleep 
apnoe (OSA) can also lead to cognitive impairment. Poor sleep and sleep disorders 
may present a significant risk factor for the development of dementia. In this review, the 
underlying mechanisms and the role of sleep and sleep disorders in the development of 
neurocognitive disorders [dementia and mild cognitive impairment (MCI)] and how the 
presence of sleep disorders could direct the process of diagnosis and management of 
neurocognitive disorders will be discussed.
Keywords: sleep, sleep disorders, cognition, dementia, neurocognitive disorders
BACKGROUND
The worldwide prevalence of neurocognitive disorders [dementia and mild cognitive impairment 
(MCI)] is increasing. Dementia occurs when the brain is damaged and is characterized by memory 
loss, alongside thinking, problem-solving, or language difficulties.
Alzheimer’s disease (AD) is a neurodegenerative disorder in which there is a progressive decline 
in cognitive function. It is the most common cause of dementia. In 2010, the worldwide prevalence 
of AD was estimated to be 35.6 million (1). While the worldwide prevalence for those aged 60 or 
above is estimated between 5 and 7%, a higher prevalence in Latin America (8.5%) and a distinctively 
lower prevalence in the four sub-Saharan African regions (2–4%) are reported. The number of cases 
is rising and is expected to double every 20 years, reaching approximately 115.4 million by 2050. The 
economic consequence of this disease is immense. In 2010, it was estimated that the annual cost of 
dementia was $604 billion dollars (2).
Our studies have shown that sleep duration is associated with an increase in all-cause mortality 
(3). In this review, the relationship between sleep and cognitive function and the role sleep and 
sleep disorders may have in the prevention, development, and treatment of neurocognitive disorders 
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will be considered. Underlying mechanisms are briefly examined 
along with the public health importance.
Sleep Architecture
Sleep is not a quiescent state. Two processes govern sleep: the first, 
the homeostatic process, is often referred to as the “sleep drive,” 
and increases the longer the individual has been awake. The 
second, the circadian system, refers to the 24-h sleep-wake cycle 
and governs many physiological processes including production 
of hormones (e.g., melatonin), gene expression, and body tem-
perature. Sleep and wake cycles are controlled by the pacemaker 
activity of the superchiasmic nucleus in the hypothalamus region 
of the brain but can be disrupted by diseases of the nervous 
system causing disordered sleep.
The high level of brain activity can be detected on an elec-
troencephalogram (EEG). Sleep “architecture” consists of four 
different stages, and the first three stages (N1, N2, and N3) are 
made up of progressively deeper, non-rapid eye movement sleep 
(NREM). Sleep spindles along with K-complexes are defining 
characteristics of, and indicate the onset of, stage 2 sleep. Slow 
wave sleep (SWS), which may be referred to as deep sleep, occurs 
in Stage 3 NREM and is characterized by synchronized EEG 
activity. The fourth stage is characterized by rapid eye move-
ments (REM) sleep, which can detected by a decrease in muscle 
activity. In general, an adult will cycle through the four stages 
approximately every 90–100 min during the night but the time 
spent in each stage changes as the night progresses.
Sleep and Aging
Age-related changes in sleep have been well documented (4). 
There are changes in sleep architecture, circadian and homeo-
static processes as well as changes in the susceptibility to sleep 
disorders. As we age, total sleep quantity and quality and sleep 
efficiency decline along with the amount of time spent in deep 
sleep. As a consequence older people often find it takes them 
longer to fall asleep, that they have more fragmented sleep and 
wake up more often and earlier (4–6). Older adults also tend to 
awaken less from REM sleep and more from NREM sleep than 
young adults and have a reduced number of sleep spindles and 
K-complexes in NREM [see review in Ref. (5)].
Studies indicate that aging is associated with reduced NREM 
and SWS (7), alongside structural brain atrophy, particularly in 
the frontal lobe regions (8). In a recent study, it was shown that 
the degree of age-related atrophy of the medial prefrontal gray 
matter region of the brain is significantly associated with the 
degree of diminution of SWS activity (9).
In a large cohort study, aging has also been shown to be associ-
ated with morning preference and a decrease in sleep efficiency. 
Sleep evaluations, using polysomnography, were conducted 
in over 2,000 subjects from the cohort who did not have sleep 
disorders. Detailed analysis indicated that there might be some 
gender differences in age-related changes in sleep: While SWS 
did decrease with age, the effect appeared to be more prominent 
in men. The study also demonstrated that in NREM, there was a 
decrease in the spectral power densities within slow waves and 
fast spindles but that for theta-alpha and beta waves, the spectral 
power increased with aging. In REM, aging was associated with 
a progressive decrease in delta waves and an increase in higher 
frequency waves (10).
Sleep and Cognition (Amnestic and  
Non-Amnestic Function)
The term “cognition” refers to a range of mental processes, which 
can be grouped into two broader categories of amnestic cognitive 
function (ACF, referring to memory) and non-amnestic cognitive 
function (nACF, or non-memory). This dichotomy is important 
in relation to the progression from normal cognitive aging to 
MCI, since MCI is typically diagnosed as amnestic (aMCI) or 
non-amnestic (naMCI) subtype (11). Furthermore, it remains to 
be determined as to whether these two subtypes of MCI have 
different trajectories in relation to dementia (12–14).
It is well established that sleep plays a role in brain maturation 
and the development and maintenance of cognitive functions 
such as memory consolidation and learning (15). Although, the 
significance and functions of the various sleep stages are still 
not fully understood, there is, however, evidence showing that 
newly learned material and skills are consolidated during REM 
sleep (16). A link between brain cholinergic activity, timing, and 
density of REM sleep and cognitive functioning has also been 
demonstrated (17). Thus, deficiencies of REM sleep might cor-
relate with or predict cognitive deficits in the elderly.
The formation of long-term memories requires a process of 
consolidation, which is facilitated by sleep. The formation of 
declarative (consciously recalled) memories, which are hip-
pocampus-dependent, appears to benefit mainly from SWS (18). 
Recently, the focus has also been placed on stage 2 sleep and more 
precisely on sleep spindles, where research shows that overnight 
verbal memory retention is highly correlated with an increase in 
the number of sleep spindles (19). A hippocampal-neocortical 
framework of memory consolidation has been proposed whereby 
NREM SWS promotes the transformation of episodic memories 
from a state that depends on the hippocampus to one that is 
increasingly hippocampus-independent (20–22). Sleep depriva-
tion after learning, however, would impair this process so that 
there is a greater retrieval of memories from the hippocampus 
(23).
Sleep Quantity and Cognition
Sleep loss may be acute, consisting of one continuous extended 
wake episode, or chronic, consisting of insufficient sleep over 
multiple days. A substantial amount of research has been con-
ducted to understand the former but more recently the effect 
of chronic sleep loss has also been investigated (24–26). In one 
study, self-reported short sleep, tiredness, and fatigue were 
more strongly associated with subjective measures of cognitive 
function than with objective measures (24). Findings from the 
Whitehall II study show that adverse changes in sleep over time 
(decrease from 6, 7, or 8 h, or increase from 7 or 8 h) are associ-
ated with lower scores on a variety of cognitive function tests, but 
not memory function (27). Subtle changes in circadian phase, for 
example, those that commonly occur in the general population 
after returning to work after later weekend sleep may also affect 
cognitive function. One study demonstrated that memory and 
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verbal fluency tasks are significantly reduced on Monday morn-
ing following delayed weekend sleep (28).
Sleep Quality and Cognition
Sleep quality is a measure of how well we actually sleep during 
the night. It is usually assessed via self-reported frequency of 
nocturnal awakenings; difficulty initiating sleep; waking up early; 
or waking up feeling tired, using validated tools such as the PSQI 
(29). Sleep quality may also play an important role in cognition. 
One study, in elderly women, however, found that while disturbed 
sleep was associated with an increased risk of developing a cogni-
tive impairment, it was not associated with accelerated cognitive 
decline (30).
The Maastricht Ageing Study (MAAS) found that in middle 
aged and older adults subjective sleep complaints (i.e., difficulty 
falling asleep, waking up too early, and restless or disturbed 
sleep) were negatively associated with cognitive performance at 
the 3-year follow-up: The strongest effect being seen with early 
waking. The effects disappeared, however, after adjustment for 
depression, raising the question of whether poor quality of sleep 
leads directly to poor cognitive function, or whether poor sleep 
causes an increase in depressive symptoms, which then results in 
cognitive decline (31).
Sleep and Cognitive Decline with Age
Cognitive aging appears to be a very heterogeneous process. It is 
associated with a decline in working memory and new episodic 
memory performance with relative sparing of semantic memory, 
recognition memory, and priming [see review in Ref. (5)]. While 
many neuronal changes that are associated with cognitive decline 
appear to begin during middle age (32), the rate of decline for 
individuals appears to vary considerably (33). Furthermore, while 
studies have demonstrated that poor sleep (quantity, quality, and 
efficiency) are associated with cognitive decline (34). In a recent 
study, looking at 3,968 male and 4,821 female white participants, 
aged 50 years and over, from the English Longitudinal Study of 
Ageing (ELSA), we demonstrated that the relationship between 
sleep (quantity and quality) and cognition may vary with age. 
Whereas in the younger age group (50–64  years), both short 
(<6 h per night) and long (>8 h per night) sleep were associated 
with lower amnestic and non-amnestic scores, in the older age 
group (65+ years), associations were only significant for long 
sleep. Furthermore, while sleep quality was associated with both 
amnestic and non-amnestic scores in the older age group, it was 
not in the younger age group. These effects were regardless of 
duration of sleep (35). These observations need to be fully inves-
tigated in longitudinal studies.
MeCHANiSMS UNDeRLYiNG 
NeUROCOGNiTive DiSORDeRS: THe 
ROLe OF SLeeP
Amyloid-β
Alzheimer’s disease is associated with the accumulation of 
amyloid-β (Aβ) in extracellular plaques in the brain. This may 
result from either increased production or decrease in Aβ 
clearance. This accumulation is thought to begin many years 
before the symptoms of AD are evident. It is now known that 
the concentrations of Aβ show diurnal variation with the levels 
rising during wakefulness and falling during sleep (36, 37). It 
has been suggested that sleep facilitates the removal of Aβ. A 
recent study in mice showed that during sleep, there was a 60% 
increase in interstitial space and a concomitant increase in the 
exchange of cerebrospinal fluid with interstitial fluid. This in turn 
increased the rate of Aβ clearance; thus facilitating the removal 
of these harmful waste proteins that had built up between brain 
cells during waking hours (38). It has been postulated that sleep 
disturbances may inhibit this process and may be important in 
the pathogenesis of AD. Indeed, evidence suggests that individu-
als who are cognitively normal but who have biomarker evidence 
of amyloid plaque formation have worse quality sleep than indi-
viduals without evidence of plague formation. The study, which 
used actigraphy to measure sleep, demonstrated that both sleep 
efficiency and wake up time after sleep onset were effected (39).
Tau-Phosphorylation
Alzheimer’s disease is associated with the accumulation of 
neurofibrillary tangles (NFT) in the brain. These are composed 
of a highly phosphorylated form of the microtubule-associated 
protein tau, which unlike the non-phosphorylated form, is unable 
to bind to microtubules (40). Several kinases are implicated in 
hyper-phosphorylation of tau including c-Jun N-terminal kinase 
(JNK), which is also implicated in the deposition of amyloid 
plaque in AD brain (41).
Phosphorylation of tau via the extracellular signal-regulated 
kinase (ERK) pathway may occur under conditions where oxygen 
is lacking (hypoxia), which is a common feature of one of the 
most common sleep disorders known as Obstructive Sleep Apnoe 
(OSA). This in turn triggers neuronal degeneration and axonal 
dysfunction in both the cortex and brainstem (42) and may trig-
ger cerebral amyloidogenesis (43).
inflammation
Inflammatory processes play a key role in the association between 
sleep disturbances and cardiovascular disease (44). Likewise, it is 
possible that inflammatory mechanisms may play a crucial role 
in the relationship between sleep and cognition (35) and in the 
sleep-associated development of neurocognitive disorders (45). 
Studies indicate that neuro-inflammation is characterized by the 
activation of microglia, which are the principal immune cells of 
the central nervous system (CNS) and astrocytes, which are part 
of the blood–brain barrier. Their function is primarily to protect 
the CNS, but activation of these cells leads to the release of pro-
inflammatory cytokines and chemokines, which may mediate 
cellular damage as well (46).
In a recent study, transcriptome analysis demonstrated that in 
26 individuals, 1 week of insufficient versus sufficient sleep led to 
a change in the gene expression of 711 genes, which were up- or 
down-regulated (47). Many of these genes were involved in cir-
cadian biology and sleep homeostasis as well as oxidative stress, 
metabolism, inflammatory, immune, and stress responses. These 
changes in gene expression may be involved with the negative 
effects of sleep loss on health.
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Melatonin Levels
Melatonin, which is produced by the pineal gland at night, plays 
a major role in regulation of the biological clock and the sleep–
wake cycle. Studies indicate that melatonin levels are decreased in 
AD (48) and, reduced melatonin levels correlate with the severity 
of mental and sleep impairments in patient with dementia (49). 
Fast-release melatonin supplements given at bedtime may, how-
ever, improve cognitive and emotional performance and sleep/
wake cycle maintenance in patients with MCI (50, 51).
Genotype
Apolipoprotein-E Genotype
Apolipoprotein-E (APOE) genotype is the strongest genetic risk 
factor for AD almost half of all AD patients have at least one ϵ4 
allele (52). The gene is important in lipid metabolism and cho-
lesterol transport and polymorphic variation is associated with 
cardiovascular disease (53). The ϵ4 allele is also pro-inflammatory 
and is associated with an increase in C-Reactive Protein (CRP) in 
population studies (54). Individuals with this genotype accumu-
late more Aβ are at high risk of developing AD. Studies indicate 
that that effect of the adverse APOE genotype may be amplified 
by sleep disruption (55–59). Moreover, better sleep consolidation 
has been shown to attenuate the effect of APOE genotype on 
incident AD (60).
Circadian Clock Genes
A single night of wakefulness can alter the epigenetic and tran-
scriptional profile of core circadian clock genes in key metabolic 
tissues. A recent study looked at the association between circa-
dian locomotor output cycle kaput (CLOCK) gene rs 4580704 
C/G with susceptibility of AD. It was found that among APOEϵ4 
non-carriers, C carriers in CLOCK gene were associated with 
a high susceptibility of AD; however, among APOEϵ4 carriers 
the functional polymorphism of clock gene rs 4580704 C/G was 
not associated with AD susceptibility (61). It remains to be seen 
if the expression of other circadian genes is altered in dementia 
patients.
ROLe OF SLeeP AND SLeeP 
DiSTURBANCeS iN THe DeveLOPMeNT 
AND MANAGeMeNT OF 
NeUROCOGNiTive DiSORDeRS
Findings from prospective studies of sleep and cognitive outcomes 
along with results from observational and experimental studies 
suggest that poor sleep is a risk factor for cognitive decline and 
the development of AD [see review in Ref. (62)]. Furthermore, 
a study in JapaneseAmerican men without dementia showed 
that those individuals who report Excessive Daytime Sleepiness 
(EDS) at baseline are twice as likely to be diagnosed with incident 
dementia at 3-year follow-up compared to those without EDS 
(63). A similar finding was also reported in elderly French men 
and women (64).
Sleep problems are a common occurrence in those with MCI 
(65) and dementia (66). The importance of sleep problems in the 
development, progression, management, and treatment of these 
disorders is still not fully recognized. The sleep issues may be 
underreported by the sufferer or carer at early stages but may lead 
to behavioral problems that are predictive of future placement of 
an individual in a care home (67). Nevertheless, there is growing 
evidence to support that sleep might be useful as a surrogate 
marker for Preclinical AD (68) and, there is a need to improve 
sleep in at risk individuals.
Individuals with dementia experience highly fragmented 
sleep, with periods of night-time wakefulness and frequent day-
time napping (66). In general, in individuals with dementia, the 
proportion of sleep at night that is spent in the lighter stages of 
sleep is increased and there is marked decrease in time spent in 
the more restorative SWS. In the latter stages of dementia, emo-
tional and behavioral changes may become more problematic 
and these may be associated with a decrease in observed REM 
sleep (69, 70). Overall, sleep in people with dementia is lighter 
and shorter, as well as shifted to occur earlier in the day compared 
to a premorbid state.
Sleep impairments and changes in sleep architecture are 
characteristic features of AD (71). Increased stage 1 sleep and 
reduced SWS, as well as decreased sleep spindles, have been 
reported (72, 73).
ROLe OF SLeeP DiSORDeRS iN 
DeveLOPMeNT OF NeUROCOGNiTive 
DiSORDeRS
Sleep-disordered breathing (SDB) is very common in the elderly, 
with reported prevalence of between 24 and 42% (74). It refers 
to conditions, which are characterized by intermittent reduction 
(hypopnea) or cessation (apnea) of breathing due to narrowing 
of the upper airways, which in turn leads to hypoxia. Cessation 
of breathing during sleep causes sleep fragmentation and arousal 
for sleep and subsequent EDS. It is associated with an increase in 
neurocognitive impairments (56, 75–77).
Sleep Apnea
The most common form of sleep apnea is OSA or obstructive 
sleep apnea syndrome (OSAS). OSA is characterized by recur-
rent sleep fragmentation and EDS, chronic intermittent hypoxia 
(CIH), hypercapnia, hypoventilation, peripheral and central 
inflammation, and changes in cerebral perfusion and glucose 
metabolism. Research suggests that the specific brain damage 
associated with OSAS could increase the risk of developing 
dementia (78). SDB may exacerbate cognitive dysfunction in AD 
(79). Indeed, positive correlations between the number of apneas 
occurring per hour (apnoe index) and severity of dementia in AD 
have been reported (80). It has been estimated that the prevalence 
of OSA in patients with dementing illnesses may be as high as 
60% (81). But, it remains unclear, however, as to whether SDB 
precedes cognitive impairment or vice versa.
insomnia and Hypersomnia
In the population of Western Europe, the estimated prevalence 
of insomnia is between 10 and 35% (82). Furthermore, there is 
increasing evidence to suggest that insomniacs are at increased 
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risk of cognitive decline [see review in Ref. (83)]. The detrimental 
performance may not be due to increased sleepiness; however, 
as insomniacs display a state of generalized hyperarousal with 
increased multiple sleep latency test (MSLT) scores (84).
Hypersomnia, which refers to either EDS or an excessive 
time spent sleeping, is a common feature of OSA and effected 
individuals have great trouble staying awake during the day. It is 
associated with neurocognitive impairments in both adults (85) 
and children (86).
Circadian Rhythm Sleep Disorders
The term “circadian rhythm sleep disorder” describes a chronic 
condition in which an individual’s circadian rhythm of sleep and 
wakefulness is persistently or periodically out of phase with the 
expected environmental pattern. It is believed to occur when the 
biological pacemakers are decoupled from external cues as may 
occur for example in blind individuals. Several circadian sleep 
disorders have been classified including delayed sleep phase syn-
drome (DSPS), advanced sleep phase syndrome (ASPS), irregular 
sleep–wake patterns, and non-24-h sleep–wake syndrome in 
blind and sighted persons (87). Shift work and jet lag can also 
cause temporary misalignment of the circadian sleep-wake 
rhythm with environmental patterns.
Circadian Rhythm Disorders
Sleep-wake disturbances are a highly prevalent and often 
disabling feature of AD. There are changes in several biological 
systems including core body temperature control, melatonin 
secretion, and circadian variability. It has also been suggested that 
sleep–wake disturbances might be due to accumulation of Aβ. It 
is possible that this may be a reciprocal relationship as chronic 
sleep deprivation increases amyloid plaque deposition, and sleep 
extension results in fewer plaques in experimental models (88). 
Furthermore, Aβ follows a diurnal pattern in that concentrations 
rise during wakefulness and fall during sleep (36, 37). Insomnia 
and circadian rhythm disorders are common causes for both 
caregiver burden and early institutionalization in patients for 
dementia (89, 90).
ReM Sleep Behavioral Disorder
Rapid eye movement sleep behavior disorder (RBD) is a sleep dis-
turbance that commonly occurs in Dementia with Lewy bodies 
(DLB) (91). It is a condition in which the normal paralysis that is 
associated with REM sleep does not occur; sufferers are able to act 
out their dreams or may sleepwalk become during sleep. It usually 
precedes cognitive impairment by years if not decades (92).
PReSeNCe OF SLeeP DiSORDeRS 
COULD DiReCT THe PROCeSS OF 
DiAGNOSiS OF NeUROCOGNiTive 
DiSORDeRS
Poor sleep quality can be an early sign of amnestic cognitive 
decline (93). Furthermore, EDS may not only be an early marker 
but may also potentially be a reversible risk factor for cognitive 
decline and onset of dementia (64).
Neuroimaging, Sleep and Neurocognitive 
Disorders
Amyloid plaque formation causes neuronal damage far before 
cognitive impairment becomes manifest (94), which makes 
interventions targeting these pathological changes more chal-
lenging. There is therefore a need to develop early screening 
techniques. Amyloid may be imaged using the PET Pittsburgh 
compound (PiB-Pet). A recent cross-sectional study has shown 
that increased brain Aβ is accompanied by lower peripheral levels 
of Aβ. Moreover there was a relationship between PiB binding 
and plasma Aβ (95). It may therefore be possible to use plasma 
Aβ combined with PiB binding as a risk biomarker. Although, it 
would be impractical to offer such screening to all individuals at 
risk of neurodegenerative disorders and other simpler risk mark-
ers are still needed.
Self-reported short and poor quality sleep in community-
dwelling older adults is associated with greater Aβ burden (58). 
Likewise, in a recent study, it was shown that among older adults 
with MCI an increase in sleep SDB, as measured by polysomnog-
raphy, was associated with greater Aβ deposition as measured by 
PiB-PET (59).
It is possible that sleep may normally play a vital role in 
removing potentially neurotoxic substances that accumulate 
in the awake state (38) and that sleep problems and sleep 
disorders may be an early marker of future neurocognitive 
disease development and treatment of sleep and sleep dis-
orders might be modifier of risk in those who have a high 
amyloid load.
PReSeNCe OF SLeeP DiSORDeRS 
COULD DiReCT MANAGeMeNT AND 
TReATMeNT OF NeUROCOGNiTive 
DiSORDeRS
Research has shown that treatment of OSA via CPAP improves 
some aspects of cognitive function in dementia patients as well as 
in non-demented elderly patients with OSA (79, 96). It remains 
to be determined if such treatments might prevent or slow future 
cognitive decline, leading to dementia.
Pharmacological Sleep intervention in 
Dementia
Short-term sleep disturbances are treated using amongst oth-
ers, antidepressants, benzodiazepines, and antihistamines. 
Benzodiazepines may decrease sleep the time taken to get to sleep 
“sleep latency” but drug therapies are not without side effects 
and long-term use may lead to increased daytime sleepiness and 
rebound insomnia (97).
A recent study demonstrated that MCI patients, who received 
fast-release melatonin at bedtime for between 15 and 60 months, 
exhibited significantly better performance on cognitive function 
tests compared to those with MCI who did not receive mela-
tonin. Furthermore, it was reported that the group that received 
melatonin therapy required far less benzodiazepines to treat their 
associated sleep disturbances (51).
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Non-Pharmacological Sleep interventions 
in Dementia
Many studies have previously focused on exercise, light or 
Cognitive Behavioral Therapy (CBT) for the treatment of sleep 
problems (45, 97). Exercise is important for physical and mental 
health and one study indicated that exercise may promote more 
restful sleep in adults (98). Bright light may be used to treat 
circadian rhythm disorders but there is a need to investigate this 
treatment further so as to develop gold standards for timing, 
mode of delivery, wavelength of light etc.
It remains to be seen if other interventions including CBT, to 
address any unhelpful beliefs and anxieties, might also be effec-
tive. Interventions may also include educating both carer and 
suffer with regards to how to improve and maintain good sleeping 
patterns. For example, by adapting the sleeping environment so 
that is quiet and dark, ensuring that there is a good pre-sleep wind 
down and ensuring that the sufferer does not spend time in the 
bedroom when they are not supposed to be. Social interactions 
might also be beneficial to sleep (97). On-going treatment for 
other conditions also needs to be considered as some blood pres-
sure medication may affect sleep (99).
Further studies are required to determine if the treatment of 
sleep disturbances and sleep disorders may delay or prevent the 
development of AD and dementia. However, given the increas-
ing population evidence to suggest that good sleep is required 
for general mental health and wellbeing it is important that the 
sufferers’ sleep does not disrupt the carers’ sleep, increasing their 
health burden.
Clinical Trials of Sleep interventions in 
Dementia
Improving Sleep Quality
A recent randomized clinical control trial demonstrated that low-
intensity physical and mental activities could lead to an increase 
in self-reported sleep quality in older adults with self-reported 
cognitive and sleep difficulties (100). Further long-term studies 
are required with objective sleep measures to validate such stud-
ies and to see if they prevent cognitive decline.
Use of Prolonged-Releases Melatonin Therapy
In individuals with mild to moderate AD (n =  80) prolonged-
release melatonin (PRM), given with standard therapy, led to a 
significantly better cognitive performance than those treated with 
placebo (101). These results contribute to the evidence that sug-
gests that there may be a causal link between sleep and cognitive 
decline.
To date, it is not clear whether improvement to sleep of indi-
viduals with established sleep disturbances would delay progres-
sion of the disease. Likewise, whether treatment of early signs of 
sleep disturbances would lead to better outcomes and reduce the 
need to place the sufferer in a home. Further studies are required 
to determine if early interventions might (i) delay cognitive 
decline, (ii) improve carer stress and future health outcomes, and 
(iii) allow the individuals to be managed at home for longer rather 
than in care.
PUBLiC HeALTH iMPORTANCe AND 
POLiCY iMPLiCATiONS
Sleep is an integral part of life. Its importance for good physi-
cal and mental health is becoming increasing apparent (6) and 
this may be of particular relevance for older adults. The role of 
sleep-related cognitive failure in major incidents and disasters 
has received much attention, as their consequences are often 
catastrophic (102, 103). As the rate of dementia is expected to 
increase dramatically across the world, it is important to fully 
understand the role that sleep and sleep disorders play in the 
prevention, development, and management of this disorder. It is 
important to increase the public awareness of the importance of 
sleep and to facilitate the early detection of sleep problems and 
disorders.
Given the emerging important relationship between sleep 
and cognition and cognitive impairment, assessment of sleep 
should be part of clinical assessment of patients presenting with 
cognitive impairment. To this end, the sleep study group of the 
Italian dementia research association (SINDem) has recently 
put forward recommendations for the clinical assessment and 
management of sleep disorders in individuals with MCI and 
Dementia (104). Indeed, intellectual decline associated with OSA 
may be misinterpreted as early dementia but may improve with 
appropriate OSA treatment (105). Knowledge of any underlying 
sleep disorders may also potentially affect the dementia diagnosis 
and subsequent management. Sleep apnea syndrome constitutes 
more than 8% of patients presenting with cognitive impairment 
in young adults, and it is imperative that this potentially revers-
ible form of cognitive impairment is identified and treated early 
(106). This is particularly important as OSA has been identified 
as a risk factor for development of future dementia (107) and 
when treated with CPAP slower progression of the dementia was 
observed (108).
Studies are required to see if improvements in sleep can delay 
cognitive decline in at risk individuals. And research is needed 
to further explore the therapeutic effects but also potentially 
adverse effects of sleep interventions in individuals with known 
sleep disorders. Identifying, which individuals might be at high 
risk of dementia or, who may have underlying sleep problems, 
would allow the identification of individuals who might benefit 
from targeted sleep intervention. However, it is also important to 
appreciate that patients with dementia are at higher risk of being 
prescribed sleeping tablets (109–111) and, for those dementia 
patients with undiagnosed OSA the use of hypnotics may exacer-
bate cognitive impairment due to drug side effects and worsening 
of the sleep disorder (112).
It is necessary to explore the mechanisms underlying demen-
tia and to determine if there may be different treatment regimens 
appropriate for different causative pathways. Early diagnosis of 
sleep disorders and sleep problems associated with dementia is 
required and referral routes need to be clearly agreed. There is a 
need for a good evidence base with regards to the effectiveness of 
proposed interventions in patients with dementia, which needs to 
be derived from large evidence–based clinical trials with objec-
tive measurements of sleep.
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CONCLUSiON
A vast amount of research has been conducted into the effect of 
sleep and sleep disorders on cognition. Age-dependent changes 
in sleep have been well documented. Studies suggest that a 
“sufficient” quantity and quality of sleep are required for many 
aspects of both memory and non-memory cognitive function 
(30). The amount of sleep that constitutes “sufficient” sleep, how-
ever, continues to be debated. Nevertheless, it is generally agreed 
that people at the extremes of the sleep distribution, i.e., short 
(<5 h) and long (>9 h) sleepers are subject to cognitive deficits 
and accelerated cognitive aging. Proper alignment between sleep-
wakefulness and internal circadian time is also crucial for optimal 
cognitive performance. It is accepted that many individuals with 
dementia have sleeping problems but despite this sleep problems 
in dementia and, the possibility that poor sleep may contribute to 
the development and progression of dementia is largely ignored. 
New clinical guidelines are required. Sleep disturbances and sleep 
disorders need to be carefully investigated using sleep history, 
physical examination, questionnaires etc., in both individuals 
with and in those at risk of development of dementia.
Further research is required to understand the associations 
and mechanisms involved in more detail, where the findings 
could have huge impacts in many areas of medicine, from normal 
aging to neurocognitive disorders and public health. Evidence-
based research is required to develop a framework for diagnosis 
and treatment of sleep disorders, especially in patients with 
dementia.
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